Combigene Investor Relations Material

CombiGene AB is a biotechnology company based in Sweden, focusing on developing gene therapies for severe neurological and psychiatric disorders. The company's primary projects include treatments for drug-resistant focal epilepsy and severe chronic pain. CombiGene utilizes gene therapy vectors, specifically adeno-associated virus (AAV) vectors, to deliver therapeutic genes. The company operates in collaboration with external research entities and contract research organizations to develop its therapeutic candidates from preclinical stages to proof of concept, aiming for subsequent commercialization through strategic partnerships. The company is headquartered in Lidingö, Sweden, and its shares are listed on the Nasdaq Stockholm.